A Bausch + Lomb drug from a 2025 acquisition missed primary and secondary goals of a Phase 2 test in glaucoma. Bausch now plans to develop this drug for geographic atrophy, aiming to succeed where Allergan, now an AbbVie subsidiary, fell short in the clinic.
The deal is a win-win for both companies.
By reducing administrative burden and redesigning workflows around human needs, it creates space for what matters most: connection between clinicians and patients.
The company wants to make its GoCheckKids photoscreening app available to improve access to screening for amblyopia and visual acuity.
RetroSense Therapeutics, an Ann Arbor optogenetics startup, is developing an algae-based gene therapy that could restore functional sight in those with congenital vision loss disorders.